Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Nov 06, 2018 12:50pm

116 Views

Post# 28931560

RE:Citagenix

Also on the Implant screen says 929 results, when sorted in "Most Popular" two of citagenix products come up in the first screen (top 30) products.

I'd say thats good news.
Also about 30 products come up in the top 225.

It also lists that it has 152 Citagenix products on the website.

I'm still hopeing we see more sales for Citagenix in next quarter results. If US sales pick up we might have a chance to be CF+

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading